Op2Lysis
Boulogne-billancourt
About Op2Lysis
Op2Lysis is a neurotic drug developer working on a treatment for hemorrhagic stroke. The company's product is a thrombolytic drug that conveniently dissolves the intracerebral hematoma that occurs after a hemorrhagic stroke, allowing patients to avoid substantial disability and surgery. It was designed to be injected locally via a catheter into the hematoma's core, using micro-invasive surgery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.9M
- Last round: Grant (Oct 2021)
- Website: op2lysis.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Wellness
Social Profiles
Canonical: https://fsome.com/organization/op2lysis-74578 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.